|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2023―Feb―22 |
COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review |
Juan I. Ruiz, Maria A. Lopez-Olivo, Yimin Geng, Maria E. Suarez-Almazor |
2 |
[GO] |
2021―May―14 |
Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors |
Ai-Tram N. Bui, Kevin Tyan, Anita Giobbie-Hurder, Isaac A. Klein, Michael P. Manos, Leyre Zubiri, et al. (+6) Kerry Reynolds, Shilpa Grover, Gerald L. Weinhouse, Patrick A. Ott, Nicole R. LeBoeuf, Osama Rahma |
3 |
[GO] |
2021―Jan―29 |
Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers? |
Aldo Venuti, Sara Donzelli, Paola Nisticò, Giovanni Blandino, Gennaro Ciliberto |
4 |
[GO] |
2020―Nov―16 |
The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers |
Diviya Gupta, Shumei Kato, Razelle Kurzrock |
5 |
[GO] |
2020―Nov―16 |
COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining |
Aakash Desai, Vivek Subbiah |
6 |
[GO] |
2020―Aug―06 |
Repurposing Interleukin-6 Inhibitors to Combat COVID-19 |
Shumei Kato, Razelle Kurzrock |
7 |
[GO] |
2020―Aug―06 |
Reflecting on COVID-19: The Hong Kong Experience of Flattening the Curve Without Lockdown |
Herbert H. Loong |
8 |
[GO] |
2020―Mar―17 |
Are Cancer Patients at Higher Risk of Death with COVID-19?Are Cancer Patients at Higher Risk of Death with Coronavirus Disease-19? |
JacobJ Adashek, Joud Hajjar, RoyF Chemaly, Razelle Kurzrock |